PURPOSE: The purpose of this study was to analyse the outcome and its influencing factors in patients whose therapy was converted from calcineurin inhibitors (CNI) to sirolimus (SRL) due to chronic allograft nephropathy (CAN). MATERIALS AND METHODS: Therapies of 78 patients (44 men) with CAN from three European transplant centres were converted from CNI therapy to SRL and followed 24 months. Slopes for creatinine clearance before and after conversion were calculated. Influencing factors were analysed by a multivariance analysis. RESULTS: The slope of the creatinine clearance improved significantly (-0.90 vs. -0.34 ml min(-1) month(-1); p < 0.01). In patients whose therapy was converted from cyclosporine A (CyA) to SRL, the slope improved significantly, whereas conversion from Tacrolimus (Tac) to SRL did not affect the slope. The benefit was more pronounced in (1) patients with low or moderate baseline creatinine clearance, (2) patients receiving SRL after conversion without additional mycophenolate mofetil and (3) patients with low or moderate proteinuria. CONCLUSION: Conversion from CyA to SRL but not from Tac to CRL is associated with a reduced loss of renal allograft function in patients with CAN.
PURPOSE: The purpose of this study was to analyse the outcome and its influencing factors in patients whose therapy was converted from calcineurin inhibitors (CNI) to sirolimus (SRL) due to chronic allograft nephropathy (CAN). MATERIALS AND METHODS: Therapies of 78 patients (44 men) with CAN from three European transplant centres were converted from CNI therapy to SRL and followed 24 months. Slopes for creatinine clearance before and after conversion were calculated. Influencing factors were analysed by a multivariance analysis. RESULTS: The slope of the creatinine clearance improved significantly (-0.90 vs. -0.34 ml min(-1) month(-1); p < 0.01). In patients whose therapy was converted from cyclosporine A (CyA) to SRL, the slope improved significantly, whereas conversion from Tacrolimus (Tac) to SRL did not affect the slope. The benefit was more pronounced in (1) patients with low or moderate baseline creatinine clearance, (2) patients receiving SRL after conversion without additional mycophenolate mofetil and (3) patients with low or moderate proteinuria. CONCLUSION: Conversion from CyA to SRL but not from Tac to CRL is associated with a reduced loss of renal allograft function in patients with CAN.
Authors: Jacques J Sennesael; Jean Louis Bosmans; Jean Paul Bogers; Dierik Verbeelen; Gert A Verpooten Journal: Transplantation Date: 2005-12-15 Impact factor: 4.939
Authors: J C Ruiz; F Diekmann; J M Campistol; A Sanchez-Fructuoso; C Rivera; J Oliver; G Fernandez-Fresnedo; M Arias Journal: Transplant Proc Date: 2005-11 Impact factor: 1.066
Authors: Giovanni Stallone; Barbara Infante; Antonio Schena; Michele Battaglia; Pasquale Ditonno; Antonia Loverre; Loreto Gesualdo; Francesco Paolo Schena; Giuseppe Grandaliano Journal: J Am Soc Nephrol Date: 2005-10-19 Impact factor: 10.121
Authors: Reinaldo Bestetti; Tatiana A D Theodoropoulos; Emmanuel A Burdmann; Mário Abbud Filho; José A Cordeiro; Daniel Villafanha Journal: Transplantation Date: 2006-03-15 Impact factor: 4.939
Authors: Fritz Diekmann; Klemens Budde; Federico Oppenheimer; Lutz Fritsche; Hans H Neumayer; Josep M Campistol Journal: Am J Transplant Date: 2004-11 Impact factor: 8.086
Authors: Fritz Diekmann; Klemens Budde; Torsten Slowinski; Federico Oppenheimer; Lutz Fritsche; Hans H Neumayer; Josep M Campistol Journal: Transpl Int Date: 2007-11-12 Impact factor: 3.782
Authors: John Stoves; Charles G Newstead; Andrew J Baczkowski; Geoffrey Owens; Marius Paraoan; Abdul Q Hammad Journal: Nephrol Dial Transplant Date: 2004-05-25 Impact factor: 5.992